Navigation Links
Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
Date:1/28/2008

BERKELEY, Calif., Jan. 28 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused on developing therapies for cardiovascular disease, today announced the appointment of Gregory W. Schafer to its board of directors and as chairman of the audit committee. Mr. Schafer is a seasoned biotechnology industry leader with 15 years of experience in biotechnology finance and operations.

"We are delighted to add Greg to our Board of Directors," said Peter Strumph, Chief Executive Officer of Nile. "Greg has very relevant experience from both small and large biotechnology companies. As the CFO for several publicly traded biotechnology companies, Greg has accrued experience developing and executing successful strategic plans, has first hand knowledge of capital markets and has been instrumental in building processes which are commensurate with current compliance considerations."

Mr. Schafer, 43, serves as the Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc. Prior to Onyx, from 2004 to 2006, Mr. Schafer served as a consultant to several private and public biotechnology companies. From 1997 to 2004, Mr. Schafer held various executive positions at Cerus Corporation, a public biotechnology company, including Vice President and Chief Financial Officer. Prior to joining Cerus, Mr. Schafer worked as a management consultant for Deloitte & Touche LLP. Mr. Schafer holds an MBA from the Anderson Graduate School of Management at UCLA and a BSE in Mechanical Engineering from the University of Pennsylvania.

"Nile is well positioned for future growth and achievement with its innovative cardiovascular product portfolio," said Mr. Schafer. "I look forward to contributing to the company's success."

About Nile Therapeutics, Inc.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
2. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
5. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
6. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
7. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
8. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
9. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
10. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
11. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... survive impact by the huge amounts of energy ... energy for photosynthesis. The hypothesis is that the ... the energy throughout the entire protein molecule through ... now managed to successfully ,film, this process. , ... which play a role in photosynthesis and thus ...
(Date:8/27/2014)... 27, 2014 Research and Markets ... Lactic Acid  (Biodegradable Polymer, Food & Beverage, Personal ... to 2019" report to their offering. ... with an asymmetrical carbon atom. The main applications ... food and beverage, personal care product, and pharmaceutical ...
(Date:8/27/2014)... 2014 “We are honored to be ... Ven Thangaraj, CEO of Radiant Sage. “We are offering ... the imaging corelab market to a different level. ... organizations to efficiently and effectively manage the massive amounts ... be analyzed and read by trained physicians. Being recognized ...
(Date:8/27/2014)... 2014 Flagship Biosciences LLC, a leading ... the pharmaceutical and medical device industries, has announced a ... growing company has consolidated its histology and tissue analysis ... Westminster, CO, just north of Denver. The new ... 103rd Ave., Suite 100, Westminster, CO 80021 , Tissue ...
Breaking Biology Technology:DTU researchers film protein quake for the first time 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Flagship Biosciences Announces Relocation and Expansion 2
... (Nasdaq: NPSP ) today reported its financial results ... update on its 2007 milestones and,financial guidance. Update ... partnership with Nycomed to develop,GATTEX(TM) (teduglutide) outside North America, ... corporate milestones for 2007. The company announced that it,has: ...
... Merge Healthcare (Nasdaq: MRGE ; TSX: MRG), today,announced ... NASDAQ,Listing Qualifications Panel stating that the panel determined to ... NASDAQ Stock Market,subject to the Company,s filing of its ... no later than January 29, 2008. As indicated in ...
... Mass., Nov. 1 Proteon Therapeutics,( http://www.proteontherapeutics.com ... first-in-class pharmaceuticals to address the,medical needs of ... presenting,tomorrow at the Annual Meeting of the ... Human Elastase (PRT-201) Dilates Outflow,Veins in a ...
Cached Biology Technology:NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 2NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 3NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 4NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 5NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 6NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 7NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 8NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 9NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 2NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 3Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007 2
(Date:8/27/2014)... available in German . ... most common inherited disease affecting the peripheral nervous system. ... Planck Institute of Experimental Medicine and University Medical Centre ... is impaired in rats with the disease. These cells ... as myelin, which facilitates the rapid transfer of electrical ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... advocates, campaigns against trans-fats have largely succeeded in ... aim at sugar for its potential contributions to ... still wrangling over the best way to assuage ... article in Chemical & Engineering News ... Chemical Society. , In the article, Stephen Ritter, ...
Breaking Biology News(10 mins):Potential therapy for incurable Charcot-Marie-Tooth disease 2New study throws into question long-held belief about depression 2
... female hormone estrogen is known to offer protection for the heart, ... New research from the University of California at Merced finds that ... a greater impact on girls, blood pressure than it does on ... between 13 and 17 years old, obese boys were 3.5 times ...
... reached epidemic levels, and pediatricians are on the front ... pre-conference session at 11:30 a.m. Friday, Oct. 14, before ... Exhibition in Boston. The Pediatrics for the ... Innovations in Practice," challenges pediatricians to "step it up ...
... Oct. 11, 2011 Based on its recent analysis ... with the 2011 North American Frost & Sullivan Award ... Biometric Platform™ , - the first scalable, multi-modal biometrics ... iris recognition from a single server. To ...
Cached Biology News:Gender differences in blood pressure appears as early as adolescence 2Pediatricians aim to end childhood obesity within a generation 2Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 2Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 3Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 4
... Software enables you to identify over ... can distinguish protein isoforms, protein subsets, ... also visualize peptide-protein associations and relationships ... protein identification and relative protein expression ...
... microscopes offer all of the features of ... Equipped with Koehler illumination, a centerable condenser ... B3 is the workhorse of Motic's range ... the need for re-focusing following a change ...
... Green II RNA gel stain is ... has bright fluorescence when bound to RNA ... ideal for use with either formaldehyde/agarose or ... UV transilluminators. A 500 µL unit size ...
... SYBR Green II RNA gel stain is ... bright fluorescence when bound to RNA and low ... with either formaldehyde/agarose or polyacrylamide gels using laser ... 100 minigels. A 500 µL unit size (S-7564) ...
Biology Products: